AstraZeneca files Brilinta NDA

AstraZeneca today announced it has submitted an NDA to the FDA for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is Brilinta, pending approval from the FDA. Release